Ok I’ve seen some interesting post on the licensing agreement. I’m not in any way, shape or form an expert with these agreements. Just looking for answers. But here is my understanding and feel free to correct me if I’m in error.
Provectus owns the patent on the purification process of the pharmaceutical grade Rose Bengal for (medical use). OBC is the entity that owns the IP and medical (device) used in their Photodynamic Therapy pre clinical and clinical research with Rose Bengal. (They) want to use Provectus drug (purified form of RB) to treat all these different fungal and coronial diseases. So the licensing is for the purified medical grade RB (which PB owns the patent on) to be used with their medical device for this disease treatment. They will be paying Provectus to use it worldwide for the treatment of bacterial, fungal, and viral infections of the eye.

That’s my take.